Cargando…

Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain

AIM: To evaluate the serological response against SARS-CoV-2 in a multicenter study representative of the Spanish COVID pandemic. METHODS: IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuentes, Ana, Serrano-Conde, Esther, Roldán, Carolina, Benito-Ruesca, Rafael, Mejías, Gregoria, Sampedro, Antonio, March-Roselló, Gabriel, Fernández-Natal, Isabel, Esperalba, Juliana, Rodríguez, Mario José, Martínez de Aguirre, Paula, Salas, Carlos, Roc, María Lourdes, Soria, Luis Miguel, Parra-Grande, Mónica, Montero, María Dolores, Fernández-Roblas, Ricardo, Franco-Álvarez de Luna, Francisco, Lozano, Carmen, García, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843881/
https://www.ncbi.nlm.nih.gov/pubmed/33512616
http://dx.doi.org/10.1007/s10096-020-04139-5
Descripción
Sumario:AIM: To evaluate the serological response against SARS-CoV-2 in a multicenter study representative of the Spanish COVID pandemic. METHODS: IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Spain) based on the detection of antibodies against the viral spike protein and nucleoprotein, were used. RESULTS: Approximately half of the patients presented antibodies (56.8% were IgM + IgA positive and 43.0% were IgG positive) as soon as 2 days after the first positive PCR result. Serological test positivity increased with time from the PCR test, and 10 days after the first PCR result, 91.5% and 88.0% of the patients presented IgM + IgA and IgG antibodies, respectively. CONCLUSION: The high values of sensitivity attained in the present study from a relatively early period of time after hospitalization support the use of the evaluated serological assays as supplementary diagnostic tests for the clinical management of COVID-19.